Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03804684 · ClinicalTrials.gov registry record · NA
visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry
A NA study, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT03804684: Completed NA study, sponsored by Wills Eye.
NCT03804684 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 72 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03804684, a NA study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
To determine age-adjusted reference values of the visuALL Field Analyzer (vFA) retinal sensitivity and to assess the repeatability of the measured values and compare them with those measured by a Standard Automatic Perimetry (SAP).
Primary Outcome
Mean (Average) retinal sensitivity to light as measured in decibels in multiple spots across the central and peripheral retina (entire visual field). Higher numbers translate to dimmer light which when detected means better vision.
Interventions
- DIAGNOSTIC_TEST Standard Automatic Perimetry Humphrey Field Analyzer
- DIAGNOSTIC_TEST visuALL Field Analyzer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-01-08 |
| Est. Completion | 2020-10-20 |
| Phase | NA |
What the finished NCT03804684 record still lists
NCT03804684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard Automatic Perimetry Humphrey Field Analyzer is the first listed.
NCT03804684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03804684 about?
NCT03804684 is a clinical study titled "visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry". To determine age-adjusted reference values of the visuALL Field Analyzer (vFA) retinal sensitivity and to assess the repeatability of the measured values and compare them with those measured by a Standard Automatic Perimetry (SAP).
What is the current status of trial NCT03804684?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2019-01-08. Estimated completion is 2020-10-20.
What interventions are being tested in trial NCT03804684?
The interventions under investigation include: Standard Automatic Perimetry Humphrey Field Analyzer (DIAGNOSTIC_TEST), visuALL Field Analyzer (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03804684?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03804684's enrollment target sits among peer trials
72 1089th of 2000 higher than 899 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI